These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32023740)

  • 1. [Lenalidomide, rituximab and dexamethasone for the treatment of recurrent/refractory or elderly newly diagnosed patients with primary central nervous system lymphoma: 5 cases report and literature review].
    Bai JF; Feng R; Han HX; Wang T; Li JT; Zhang CL; Liu H
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1047-1049. PubMed ID: 32023740
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.
    Yuan X; Xie Y; Xu N; Liu H; Chen P; Zhao A; Liang Y; Qian W
    Haematologica; 2024 Jun; 109(6):2005-2009. PubMed ID: 38356447
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma-a single-center retrospective study.
    Guo XL; Zhao ZY; Guo XF; Zuo YB; Li JA; Nie ZY; Ren JH
    Neurol Sci; 2024 Jun; 45(6):2931-2934. PubMed ID: 38326666
    [No Abstract]   [Full Text] [Related]  

  • 4. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide following whole-brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy.
    Bagal B; Sarma R; Dey S; Nayak L; Bonda A; Goda J; Khanna N; Dasgupta A; Kakoti S; Chatarjee A; Jain H; Epari S; Laskar S; Sengar M; Gupta T
    Br J Haematol; 2023 Apr; 201(1):150-153. PubMed ID: 36682363
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
    Ghesquieres H; Chevrier M; Laadhari M; Chinot O; Choquet S; Moluçon-Chabrot C; Beauchesne P; Gressin R; Morschhauser F; Schmitt A; Gyan E; Hoang-Xuan K; Nicolas-Virelizier E; Cassoux N; Touitou V; Le Garff-Tavernier M; Savignoni A; Turbiez I; Soumelis V; Houillier C; Soussain C
    Ann Oncol; 2019 Apr; 30(4):621-628. PubMed ID: 30698644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Wong ET; Tishler R; Barron L; Wu JK
    Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
    Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
    J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
    J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
    Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
    Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.
    Houillier C; Chabrot CM; Moles-Moreau MP; Willems L; Ahle G; Waultier-Rascalou A; Fornecker LM; Hoang-Xuan K; Soussain C
    Neurology; 2021 Sep; 97(13):628-631. PubMed ID: 34580183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.
    Birsen R; Willems L; Pallud J; Blanc E; Burroni B; Legoff M; Le Ray E; Pilorge S; Deau B; Franchi P; Vignon M; Kirova Y; Edjlali M; Houillier C; Soussain C; Varlet P; Dezamis E; Damotte D; Bouscary D; Tamburini J
    Haematologica; 2018 Jul; 103(7):e296-e299. PubMed ID: 29472354
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
    Tun HW; Johnston PB; DeAngelis LM; Atherton PJ; Pederson LD; Koenig PA; Reeder CB; Omuro AMP; Schiff D; O'Neill B; Pulido J; Jaeckle KA; Grommes C; Witzig TE
    Blood; 2018 Nov; 132(21):2240-2248. PubMed ID: 30262659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev).
    Cabanillas F; Rivera N; Acosta M; Pardo W; Solivan P; Rivera C; Liboy I
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):776-783. PubMed ID: 31591042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].
    Hu BN; Yang X; Yuan YP; Chen YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):633-637. PubMed ID: 33812443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCV salvage chemotherapy for recurrent primary CNS lymphoma.
    Herrlinger U; Brugger W; Bamberg M; Küker W; Dichgans J; Weller M
    Neurology; 2000 Apr; 54(8):1707-8. PubMed ID: 10762527
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first-line methotrexate treatment: A retrospective study.
    Zhang Y; Wang W; Zhao D; Chong W; Chen C; Zhang W; Zhou D
    Cancer Med; 2024 May; 13(9):e7193. PubMed ID: 38738459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma.
    Dührsen U; Tometten M; Kroschinsky F; Ganser A; Ibach S; Bertram S; Hüttmann A
    Blood Cancer J; 2021 May; 11(5):95. PubMed ID: 34001867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.